for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Quotient Ltd

QTNT.OQ

Latest Trade

6.75USD

Change

-0.33(-4.66%)

Volume

121,893

Today's Range

6.71

 - 

7.09

52 Week Range

2.40

 - 

11.09

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
7.08
Open
7.02
Volume
121,893
3M AVG Volume
20.47
Today's High
7.09
Today's Low
6.71
52 Week High
11.09
52 Week Low
2.40
Shares Out (MIL)
80.61
Market Cap (MIL)
570.70
Forward P/E
-5.37
Dividend (Yield %)
--

Latest Developments

More

Quotient Ltd Quarterly Loss Per Share $0.32

Quotient Ltd- Appointed Isabelle Buckle, And Catherine Larue To Board, Effective As Of Sept 1

Quotient Provides Update On COVID-19 Antibody Test Progress

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Quotient Ltd

Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market. It is engaged in developing MosaiQ, which is its technology platform. The Company develops, manufactures and commercializes the products, including antisera products, reagent red blood cells, whole blood controls and ancillary products. Its antisera products contain antibodies used to identify blood group antigens. Its antisera products are monoclonal antibodies manufactured from master cell lines it owns. Its reagent red blood cells products are composed of human red blood cells formulated to enable the identification of blood group antibodies. The Company develops, manufactures and sells conventional reagent products to original equipment manufacturers (OEMs).

Industry

Biotechnology & Drugs

Contact Info

Jtc House, 28 Esplanade

1262

Switzerland

+41.22.7169800

http://www.quotientbd.com

Executive Leadership

Heino.N.F.M von Prondzynski

Independent Chairman of the Board

Edward Farrell

Co-President, Chief Operating Officer

Jeremy Stackawitz

Co-President, Chief Commercial Officer

Franz Walt

Chief Executive Officer, Director

Peter Buhler

Chief Financial Officer, Principal Financial Officer

Key Stats

1.33 mean rating - 3 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.0K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-2.020

2019

-1.920

2020

-1.440

2021(E)

-1.337
Price To Earnings (TTM)
--
Price To Sales (TTM)
17.48
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-59.13
Return on Equity (TTM)
-50.85

Latest News

Latest News

BRIEF-Quotient Limited Added To The Russell 2000 And Russell 3000 Indexes

* QUOTIENT LIMITED ADDED TO THE RUSSELL 2000 AND RUSSELL 3000 INDEXES Source text for Eikon: Further company coverage:

BRIEF-Quotient Provides Update On COVID-19 Antibody Test Progress

* QUOTIENT LIMITED PROVIDES UPDATE ON COVID-19 ANTIBODY TEST PROGRESS, OTHER KEY DEVELOPMENTS AND Q4 AND FULL YEAR FISCAL 2020 RESULTS

BRIEF-Quotient Limited Announces CE Mark For Its Sars-Cov-2 (Covid-19) Antibody Microarray

* QUOTIENT LIMITED ANNOUNCES CE MARK FOR ITS SARS-COV-2 (COVID-19) ANTIBODY MICROARRAY

BRIEF-Quotient Ltd Announces Sars-Cov-2 (Covid-19) Antibody Test Final Performance Data

* QUOTIENT LIMITED ANNOUNCES SARS-COV-2 (COVID-19) ANTIBODY TEST FINAL PERFORMANCE DATA

BRIEF-Quotient Limited Announces Sars-Cov-2 (Covid-19) Antibody Test Performance Update

* QUOTIENT LIMITED ANNOUNCES SARS-COV-2 (COVID-19) ANTIBODY TEST PERFORMANCE UPDATE

BRIEF-Quotient Ltd Completes Sars-Cov-2 Antibody Test Development

* QUOTIENT LIMITED ANNOUNCES THE COMPLETION OF THE SARS-COV-2 ANTIBODY TEST DEVELOPMENT

BRIEF-Quotient Reports Concordance Data From Extended Serological Disease Screening Benchmark Study

* QUOTIENT LIMITED REPORTS CONCORDANCE DATA FROM EXTENDED SEROLOGICAL DISEASE SCREENING BENCHMARK STUDY Source text for Eikon: Further company coverage:

BRIEF-Quotient Ltd Announces The Sale And Leaseback Of Its Edinburgh Manufacturing And R&D Facility

* QUOTIENT LIMITED ANNOUNCES THE SALE AND LEASEBACK OF ITS EDINBURGH, SCOTLAND MANUFACTURING AND RESEARCH AND DEVELOPMENT FACILITY

BRIEF-Quotient Sees FY 2018 Revenue $24.1 Million To $24.6 Million

* QUOTIENT LIMITED UPDATES ON STATUS OF MOSAIQ PERFORMANCE AND PROVIDES THIRD QUARTER FISCAL 2018 FINANCIAL RESULTS

BRIEF-Highbridge Capital Management reports 9.92 pct passive stake in Quotient Ltd

* Highbridge Capital Management Llc reports 9.92 percent passive stake in Quotient Ltd as on October 24 - SEC filing Source text: (http://bit.ly/2y47agF) Further company coverage:

BRIEF-Quotient reports positive concordance data from Mosaiq platform

* Quotient reports positive concordance data from Mosaiq verification and validation studies for blood grouping and announces financing

BRIEF-Quotient Limited announces $40 million private placement

* Quotient Limited announces $40 million private placement and the issue of warrants to raise up to an additional $49 million

BRIEF-Quotient Ltd says sent a form of email to certain shareholders of co

* Quotient Ltd says sent a form of email to certain shareholders of co in connection with co's 2017 annual general meeting of shareholders - SEC filing

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up